DOJ Acts on Cannabis Rescheduling: What It Means for the Industry

Today, the Department of Justice and the DEA issued an order immediately moving medical marijuana from Schedule I of the Controlled Substances Act to Schedule III.

This is not full federal legalization — but it's the most significant federal action on cannabis in decades.

What This Means for the Industry

For state-licensed medical cannabis operators, the immediate practical effect is significant: Schedule III status almost certainly means the end of IRC § 280E exposure for these businesses. That's the provision that has denied cannabis companies ordinary business deductions for years. Eliminating that burden frees up real operating cash and could fuel the next wave of M&A activity in the space.

For everyone else — recreational operators, unlicensed businesses, people unjustly incarcerated — today changes little. Marijuana in any other context remains a Schedule I drug (alongside heroin and LSD).

Separately, the DOJ announced a new administrative hearing beginning June 29, 2026 to consider broader rescheduling of all marijuana. The prior Biden-era rulemaking has been scrapped and restarted. The outcome of that process will determine how far this goes.

This is historic, and it is another step in the right direction. If you hold a state-licensed medical marijuana license, now is the time to revisit your tax structure, financing, exit paths, and overall positioning before the broader rulemaking concludes.

Book a free consult today and make sure your cannabis business is prepared.